Sign Out
Myelofibrosis: Ruxolitinib (Jakavi) is indicated for the treatment of patients with myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
Polycythemia vera: Ruxolitinib (Jakavi) is indicated for the treatment of patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.
